Pro-rata rights allow an investor to participate in future financings up to the amount needed to maintain their existing ownership percentage. Often called 'preemptive rights' in legal documents. Rights are often limited to major investors above a set ownership threshold. Later lead investors sometimes ask existing holders to reduce pro-rata to make room. Super pro-rata rights let an investor buy more than its share, which is less common.

Why it matters

Coveted in oversubscribed MedTech rounds, where insiders compete with new investors for allocation. Major funds insist on pro-rata; smaller checks may not get them.

Common pitfalls

•Misunderstanding pro-rata rights can lead to significant dilution for early investors if they are unable to participate in subsequent funding rounds.
•Failing to clearly define pro-rata rights in investment agreements can result in legal disputes and delays in securing future financing.
•Overlooking the operational impact of pro-rata participation can strain a company's administrative resources during fundraising.
•Assuming all investors will exercise their pro-rata rights can lead to miscalculations in fundraising targets and available equity.
•Not considering the long-term implications of granting broad pro-rata rights on future investor interest can be a mistake.

Sources

Cooley GO: pro-rata · Cooley GO
NVCA Model Documents · NVCA
Silicon Valley Bank - Healthcare Reports · SVB
SEC capital-raising glossary: preferred stock and pro-rata rights · U.S. Securities and Exchange Commission

Open full page

Select term B to compare.

Why compare MedTech terms side by side?

MedTech terminology is full of pairs that look interchangeable but carry very different regulatory, clinical, and commercial consequences. Picking the wrong framework, pathway, or standard early in a project can add months to a submission, invalidate clinical evidence, or trigger an audit finding. Side-by-side comparison is the fastest way to surface those differences before they become costly mistakes.

Each comparison on this page pulls from the same vendor-neutral, sourced definitions used throughout the MedTech Terms glossary. You see the one-line summary, the formal definition, why it matters in practice, common pitfalls, and the primary sources (FDA guidance, EU MDR/IVDR articles, ISO/IEC standards, MDCG documents, IMDRF principles) that back each entry. That makes the comparison defensible in regulatory strategy memos, design reviews, and submission narratives.

Common comparison patterns

Regulatory pathway choice - 510(k) vs PMA, 510(k) vs De Novo, Abbreviated vs Special 510(k).
Quality systems - QSR vs ISO 13485, QMSR vs QSR.
Software classification - SaMD vs SiMD, Locked vs adaptive AI.
EU frameworks - MDR vs IVDR, CE Mark vs UKCA.
Cybersecurity artifacts - SPDX vs CycloneDX SBOM, CVE vs CVSS.
Post-market actions - Recall vs field action, Removal vs correction.

How to use this tool

Pick term A and term B from the dropdowns, or click a preset above. The URL updates with both slugs so you can bookmark or share the exact comparison with a colleague, a notified body reviewer, or your regulatory consultant. Click Open full page on either side for the complete entry, including FAQs, related terms, and the full citation list. If you are not sure which term to start with, browse the Categories view or the A-Z index.

MedTech Terms is a vendor-neutral community resource sponsored by Blue Goat Cyber. Definitions are written for educational use and are not legal or regulatory advice.